SOP DC0020.1 Hybridoma Development Initiation Page 1 of 4 Version: 2 Effective Date: June 1, 2015 Hybridoma Project Initiation Checklist Date: Company Name: Primary Contact: Secondary Contact: Phone: Fax: Phone: E-mail: E-mail: Bill to: Ship to: Fax: Project Goals: Please describe the overall goals for the antibodies you would like MBS to develop. Please include the attributes that you want the antibodies to have (for example, specificity) as well as the format(s) in which you plan to use the antibodies in your final application. Do you have any information and/or past experience with raising an antibody response against this target? Yes No If YES, please describe: Specify any known homology with endogenous mouse proteins: Cross reactants of concern: MAINE BIOTECHNOLOGY SERVICES, INC. 1037R Forest Avenue Portland, Maine 04103 USA 800-925-9476 > 207-797-5454 > FAX: 207-797-5595 email: sales@mainebiotechnology.com www.mainebiotechnology.com Page 2 of 4 SOP DC0020.1 Hybridoma Development Initiation Version: 2 Effective Date: June 1, 2015 Reagent Information: Please provide details for all possible immunogen and screening reagents available to support the project. 1 Reagent: Purpose: Protein Type of antigen: Description: Purified Peptide Lysate Carbohydrate Immunogen Screening Other Other: Other: % purity (method): Origin of Molecule: Human Viral Bacterial Other: Expression System (if applicable): Bacterial Accession # Strain: Mammalian Cell Line: Other: Amount available: 2 MW: Lyophilized Reconstitution: In Solution Buffer: Concentration: Reagent: Purpose: Protein Type of antigen: Description: Purified Storage: -80C -20C 4C pI: Peptide Lysate Carbohydrate Immunogen Screening Other Other: Other: % purity (method): Origin of Molecule: Human Viral Bacterial Other: Expression System (if applicable): Bacterial Accession # Strain: Mammalian Cell Line: Other: Amount available: 3 MW: Lyophilized Reconstitution: In Solution Buffer: Concentration: Reagent: Purpose: Protein Type of antigen: Description: Purified Storage: -80C -20C 4C pI: Peptide Lysate Carbohydrate Other: Other: % purity (method): Origin of Molecule: Human Viral Bacterial Other: Expression System (if applicable): Bacterial Immunogen Screening Other Accession # Strain: Mammalian Cell Line: Other: Amount available: MW: Lyophilized Reconstitution: In Solution Buffer: pI: Storage: -80C -20C 4C Concentration: MAINE BIOTECHNOLOGY SERVICES, INC. 1037R Forest Avenue Portland, Maine 04103 USA 800-925-9476 > 207-797-5454 > FAX: 207-797-5595 email: sales@mainebiotechnology.com www.mainebiotechnology.com SOP DC0020.1 Hybridoma Development Initiation Page 3 of 4 Version: 2 Effective Date: June 1, 2015 Antibody Controls: Please provide information about any positive control antibodies available to support the project. 1 Antibody Description: Customer can provide Please order if needed - Supplier/Cat No: Immunogen (if known): Species source: Mouse Form: Purified Antiserum Rabbit Goat Other: Goat Other: Other: Use information: 2 Antibody Description: Customer can provide Please order if needed - Supplier/Cat No: Immunogen (if known): Species source: Mouse Form: Purified Antiserum Rabbit Other: Use information: Specify what types of samples you would like provided for internal evaluation: No internal work planned. All antibody samples remain at MBS for characterization and selection. Purified hybridoma fusion product samples, discovery-scale (0.5mg average yield) Corresponding set of antibody-biotin conjugates to support matched pair studies 15mL overgrown supernatants from cryopreserved hybridoma fusion products 3-5mL supernatants from cryopreserved hybridoma fusion products Other: Please describe any planned assay work with these samples: MAINE BIOTECHNOLOGY SERVICES, INC. 1037R Forest Avenue Portland, Maine 04103 USA 800-925-9476 > 207-797-5454 > FAX: 207-797-5595 email: sales@mainebiotechnology.com www.mainebiotechnology.com Page 4 of 4 SOP DC0020.1 Hybridoma Development Initiation Version: 2 Effective Date: June 1, 2015 Hybridoma Development Timeline MBS recommends purifying hybridoma fusion supernatants by MultiPure to allow for advanced screening and better identification of lead candidates for subcloning Immunization ~4 weeks Discovery grade monoclonal antibody samples are characterized further for end application clone selection and production. Fusion Subcloning ~4 weeks ~4 weeks Hybridoma Development ~12 weeks Optional (in vitro) Antibody Production ~4 weeks Optional (Ascites) Antibody Production ~Additional 4 weeks Antibody Production ~ 4-8 weeks (method dependent) Hybridoma Development Terms of Service Maine Biotechnology Services offers over 25 years of hybridoma development and screening expertise. Our goal is to achieve the maximum level of satisfaction for all of our customers; however it is impossible to offer an absolute guarantee that we can develop a monoclonal antibody to every immunogen or meet the specific goals originally outlined. MBS guarantees that we keep our customers informed of project status and involve them at all critical points. In-process check points allow us to strategize with the customer when needed, increasing the chance for success. Customers have the ability to terminate the project at any point and will not be invoiced for work that was not performed. Hybridoma development batch records are well maintained. All information and resulting product is confidential and the property of the customer. Thank you for choosing MBS. MBS Hybridoma Development Staff Our experienced hybridoma development team will stay in contact with you throughout your project. Contact Position E-mail Phone Ext: Carrie Rice Director of Sales crice@mainebiotechnology.com 14 Abby Culberson Sales Account Manager aculberson@mainebiotechnology.com 10 Nathalie Forster Hybridoma Project Manager nforster@mainebiotechnology.com 27 Moira Reno Lab Manager mreno@mainebiotechnology.com 24 MAINE BIOTECHNOLOGY SERVICES, INC. 1037R Forest Avenue Portland, Maine 04103 USA 800-925-9476 > 207-797-5454 > FAX: 207-797-5595 email: sales@mainebiotechnology.com www.mainebiotechnology.com